Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey I Shapiro

Showing results (41-50 of 277) with videos related to

Pageof 28
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 24, 2017
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumoursPatrick Schöffski, Michael Gordon, David C Smith, et al.
Journal of Clinical Pharmacology|April 19, 2017
Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation ApproachWan Sun, Peter J O'Dwyer, Richard S Finn, et al.
Cancer Chemotherapy and Pharmacology|October 12, 2012
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignanciesDa Zhang, Monica Mita, Geoffrey I Shapiro, et al.
JCO Precision Oncology|January 7, 2022
Clinical Efficacy of Olaparib in <i>IDH1/IDH2-</i>Mutant Mesenchymal SarcomasJoseph P Eder, Deborah B Doroshow, Khanh T Do, et al.
Investigational New Drugs|October 12, 2012
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumorsGeoffrey I Shapiro, Stewart McCallum, Laurel M Adams, et al.
Molecular Cancer Therapeutics|March 23, 2011
Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cellsDeepak Raina, Michio Kosugi, Rehan Ahmad, et al.
Molecular Cell|August 18, 2009
Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damageNeil Johnson, Dongpo Cai, Richard D Kennedy, et al.
Investigational New Drugs|June 5, 2012
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumorsGary K Schwartz, Richard D Carvajal, Rachel Midgley, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2011
The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancerGeoffrey I Shapiro, Richard Frank, Uday B Dandamudi, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2016
ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumorsJason J Luke, Patricia LoRusso, Geoffrey I Shapiro, et al.
Pageof 28

Showing results (41-50 of 277) with videos related to

Sort By:
Pageof 28
European Journal of Cancer (Oxford, England : 1990)|October 24, 2017
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumoursPatrick Schöffski, Michael Gordon, David C Smith, et al.
Journal of Clinical Pharmacology|April 19, 2017
Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation ApproachWan Sun, Peter J O'Dwyer, Richard S Finn, et al.
Cancer Chemotherapy and Pharmacology|October 12, 2012
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignanciesDa Zhang, Monica Mita, Geoffrey I Shapiro, et al.
JCO Precision Oncology|January 7, 2022
Clinical Efficacy of Olaparib in <i>IDH1/IDH2-</i>Mutant Mesenchymal SarcomasJoseph P Eder, Deborah B Doroshow, Khanh T Do, et al.
Investigational New Drugs|October 12, 2012
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumorsGeoffrey I Shapiro, Stewart McCallum, Laurel M Adams, et al.
Molecular Cancer Therapeutics|March 23, 2011
Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cellsDeepak Raina, Michio Kosugi, Rehan Ahmad, et al.
Molecular Cell|August 18, 2009
Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damageNeil Johnson, Dongpo Cai, Richard D Kennedy, et al.
Investigational New Drugs|June 5, 2012
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumorsGary K Schwartz, Richard D Carvajal, Rachel Midgley, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2011
The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancerGeoffrey I Shapiro, Richard Frank, Uday B Dandamudi, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2016
ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumorsJason J Luke, Patricia LoRusso, Geoffrey I Shapiro, et al.
Pageof 28